Brief report: Variant of hepatitis B virus with primary resistance to adefovir

被引：172

作者：

Schildgen, O

Sirma, H

Funk, A

Olotu, C

Wend, UC

Hartmann, H

Helm, M

Rockstroh, JK

Willems, WR

Will, H

Gerlich, WH

机构：

[1] Univ Bonn, Inst Med Microbiol & Immunol, D-5300 Bonn, Germany

[2] Univ Bonn, Dept Med 1, D-5300 Bonn, Germany

[3] Heinrich Pette Inst, Hamburg, Germany

[4] Inst Med Virol, D-35392 Giessen, Germany

[5] Practice Gastroenterol & Hepatol, Herne, Germany

[6] Practice Abelein Helm, Nurnberg, Germany

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 354卷 / 17期

关键词：

D O I：

10.1056/NEJMoa051214

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The reverse-transcriptase inhibitor lamivudine ( Zeffix, GlaxoSmithKline) is often treat chronic infection with hepatitis B virus ( HBV) until resistance develops. may then be switched to the reverse-transcriptase inhibitor adefovir Gilead), which has a lower frequency of resistance. Here, we describe cases of primary adefovir resistance that were sensitive to tenofovir ( Viread, All three cases involved a rare HBV variant with a valine at position 233 of transcriptase domain instead of isoleucine ( rtI233V), as in the wild-type This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir vitro.

引用

收藏

页码：1807 / 1812

页数：6

相关论文

共 27 条

[1] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[2] Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. [J].

Benhamou, Y ;

Tubiana, R ;

Thibault, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :177-178

[3] Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir [J].

Brunelle, MN ;

Jacquard, AC ;

Pichoud, C ;

Durantel, D ;

Carrouée-Durantel, S ;

Villeneuve, JP ;

Trépo, C ;

Zoulim, F .

HEPATOLOGY, 2005, 41 (06) :1391-1398

[4] Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus [J].

Dore, GJ ;

Cooper, DA ;

Pozniak, AL ;

DeJesus, E ;

Zhong, LJ ;

Miller, MD ;

Lu, B ;

Cheng, AK .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (07) :1185-1192

[5] Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B [J].

Erhardt, A ;

Reineke, U ;

Blondin, D ;

Gerlich, WH ;

Adams, O ;

Heintges, T ;

Niederau, C ;

Haussinger, D .

HEPATOLOGY, 2000, 31 (03) :716-725

[6] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences [J].

Ganem, D ;

Prince, AM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1118-1129

[7]

GANEM D, 2004, NEW ENGL J MED, V351, P351

[8] Molecular epidemiology of hepatitis B virus variants in nonhuman primates [J].

Grethe, S ;

Heckel, JO ;

Rietschel, W ;

Hufert, FT .

JOURNAL OF VIROLOGY, 2000, 74 (11) :5377-5381

[9] HIGH-LEVEL HEPATITIS-B VIRUS-REPLICATION IN TRANSGENIC MICE [J].

GUIDOTTI, LG ;

MATZKE, B ;

SCHALLER, H ;

CHISARI, FV .

JOURNAL OF VIROLOGY, 1995, 69 (10) :6158-6169

[10] Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B [J].

Hadziyannis, SJ ;

Tassopoulos, NC ;

Heathcote, EJ ;

Chang, TT ;

Kitis, G ;

Rizzetto, M ;

Marcellin, P ;

Lim, SG ;

Goodman, Z ;

Wulfsohn, MS ;

Xiong, S ;

Fry, J ;

Brosgart, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (09) :800-807